Iran Achieves Breakthroughs in Plasma-Based Therapies and Radio pharmaceutical Research

Speaking to reporters on Thursday (11 Dey) at the inauguration of the Nuclear Martyrs’ Wound Care and Treatment Unit—the country’s twelfth cold plasma–based wound treatment clinic—at Al-Zahra (SA) Educational and Medical Center in Isfahan, Eslami extended his congratulations to the Iranian people on the occasion of the birth anniversary of Imam Ali (AS). He expressed gratitude for the opportunity to inaugurate the new center during these auspicious days.

Eslami noted that this clinic differs from previously established centers as it includes both outpatient services and an inpatient ward. He explained that the clinic addresses a wide range of wounds, including chronic wounds in diabetic patients that may lead to limb amputation, as well as pressure ulcers and post-surgical wounds, which are particularly common among cancer patients. Such wounds, he added, are often prone to infection following surgery, significantly slowing the healing process and posing serious challenges to treatment outcomes. Given the large population coverage of the center, Eslami said the decision was made to establish inpatient facilities.

He described the Nuclear Martyrs’ Wound Care and Treatment Unit as one of the most advanced wound care clinics in the country, capable of providing specialized services to patients—especially cancer patients and individuals suffering from infected post-operative wounds. Patients can be hospitalized at the center and undergo one or multiple plasma therapy sessions based on medical diagnosis, before being discharged upon recovery.

The head of the AEOI emphasized that, thanks to sustained investment in this field, the public can now benefit from cold plasma technology for wound treatment at this center. He added that over the past two years, approximately 2,500 patients have been treated and fully recovered at cold plasma–based wound care clinics across the country.

Eslami underscored that cold plasma is a cutting-edge technology at the forefront of modern science and reiterated Iran’s leading role in innovative medical approaches. He cited advances in radiopharmaceuticals as a key example, noting that several scientific congresses were held this year to introduce these developments to the medical community.

Among them was the Second Congress on Plasma Medicine in Tehran, which attracted strong participation from researchers, physicians, healthcare professionals, academics, and students, highlighting the field’s long-term potential and broad acceptance within scientific and medical circles.

He further noted that earlier this month, Iran hosted its first joint congress on comprehensive cancer treatment approaches, bringing together oncologists, radiation oncologists, hematologists, surgeons, and nuclear medicine specialists for the first time.

The aim, he said, was to foster interdisciplinary synergy through advanced technologies and to examine solutions developed by the AEOI to address the increasingly aggressive progression of cancer in the country.

Referring to Iran’s scientific standing, Eslami stated that in many areas—including the production of radiopharmaceuticals and therapeutic solutions—Iran is either on par with or, in some cases, ahead of advanced countries.

He described this achievement as a source of national pride, stressing that by offering an integrated package of plasma technology, radiopharmaceuticals, and deuterated compounds to the medical community, the AEOI has taken effective steps toward advancing modern treatment methods.

He added that strengthening public awareness and scientific outreach would enhance the long-term impact of these innovations, particularly for patients battling serious diseases such as cancer.

In closing, Eslami said that Iran is currently at a highly promising stage in this field and will continue to expand and further develop these initiatives.

The twelfth specialized cold plasma–based wound treatment clinic, officially titled the Nuclear Martyrs’ Wound Care and Treatment Unit, was inaugurated on Thursday at Al-Zahra (SA) Hospital in Isfahan.

The ceremony was attended by Mohammad Eslami, Vice President and Head of the AEOI; Mehdi Jamali-Nejad, Governor of Isfahan; the President of Isfahan University of Medical Sciences; the CEO of the Plasma Technology Development Knowledge-Based Company; and a number of senior provincial officials, managers, leading academics, and prominent physicians.